Trial Profile
A Study to Evaluate the Factors Associated With Virological Response in Treatment Experienced but CCR5 Inhibitor-Naive HIV-1 Patients Who Switched to Maraviroc Containing Regimens
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Jun 2016
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 10 Jun 2016 New trial record
- 27 May 2016 Results published in the Journal of Antimicrobial Chemotherapy